This article was originally published in The Gray Sheet
Executive SummaryMaker of ThinPrep automated Pap screening system announces three-for-one stock split for shareholders of record at close of trading on Feb. 16, 2001. The additional shares will be distributed on or about March 2, the firm said in a Jan. 31 release. Upon completion of the split, Cytyc will have roughly 113.1 mil. shares outstanding
You may also be interested in...
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.